The BioPharm Brief: RNA Editing, Liver Safety, Joint Gains

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today’s update focuses on three clinical stories drawing attention across the biotech and pharmaceutical landscape: promising RNA editing data in alpha-1 antitrypsin deficiency, new semaglutide findings in liver disease, and competitive trial results in psoriatic arthritis.

First, Wave Life Sciences reported early clinical data for WVE-006, an investigational RNA editing therapy targeting alpha-1 antitrypsin deficiency. In the Phase 1b/2a study, researchers said the therapy achieved protein levels associated with the milder “MZ-like” phenotype, potentially reducing disease severity. The approach uses RNA editing rather than permanent DNA modification, a strategy that continues to gain attention as developers look for more targeted genetic medicines.

Next, Novo Nordisk presented additional analyses on semaglutide in metabolic dysfunction-associated steatohepatitis, or MASH, during EASL 2026. The company highlighted liver safety findings and subgroup analyses from the ESSENCE program, including data involving postmenopausal women and Japanese patient populations. The results add to growing evidence supporting GLP-1 therapies in liver disease management, an area receiving increasing industry focus as MASH diagnoses continue to rise globally.

And finally, UCB announced new BE BOLD trial data showing Bimzelx, or bimekizumab, demonstrated stronger joint-related outcomes than risankizumab in adults with active psoriatic arthritis. Nearly half of patients receiving bimekizumab achieved the stringent ACR50 endpoint at Week 16, compared with just over 38 percent in the comparator arm. Researchers also noted earlier improvements in joint symptoms and no unexpected safety concerns.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

• RNA editing therapy WVE-006 showed encouraging early clinical results in alpha-1 antitrypsin deficiency.
• Novo Nordisk expanded semaglutide data supporting liver safety and subgroup effectiveness in MASH patients.
• Bimzelx outperformed risankizumab on key joint outcomes in the BE BOLD psoriatic arthritis study.